Allergy Therapeutics (LSE:AGY) EV-to-Revenue : 2.53 (As of Apr. 30, 2024)

Allergy Therapeutics EV-to-Revenue Chart

Allergy Therapeutics Annual Data
	Trend	Jun14	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23
EV-to-Revenue		Get a 7-Day Free Trial					0.87	0.82	1.59	1.70	0.48

Allergy Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	1.70	-	0.48	-

Competitive Comparison of Allergy Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergy Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's EV-to-Revenue falls into.

Allergy Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Allergy Therapeutics's EV-to-Revenue for today is calculated as:

Allergy Therapeutics's current Enterprise Value is £134.56 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £53.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics  (LSE:AGY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Allergy Therapeutics's PS Ratiofor today is calculated as:

Allergy Therapeutics's share price for today is £0.029.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was £0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics (LSE:AGY) Business Description